 <h1>Cilastatin / imipenem Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to cilastatin / imipenem: powder for solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, cilastatin / imipenem may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking cilastatin / imipenem:</p><p>
<i>More common</i>
</p><ul>
<li>Confusion</li>
<li>convulsions (seizures)</li>
<li>dizziness</li>
<li>pain at place of injection </li>
<li>skin rash, hives, itching, fever, or wheezing</li>
<li>tremors</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Dizziness</li>
<li>increased sweating</li>
<li>nausea or vomiting</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Fever</li>
<li>severe abdominal or stomach cramps and pain</li>
<li>watery and severe diarrhea, which may also be bloody (these side effects may also occur up to several weeks after you stop receiving this medicine)</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of cilastatin / imipenem may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Diarrhea</li>
<li>nausea and vomiting</li>
</ul><p>
<!-- end powder for solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to cilastatin / imipenem: injectable powder for injection, intramuscular powder for injection</i></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Phlebitis/thrombophlebitis at the injection site</p>
<p><b>Uncommon</b> (0.1% to 1%): Pain at the injection site, erythema at the injection site, vein induration, local pain and induration at the injection site</p>
<p><b>Frequency not reported</b>: Infused vein infection, injection site irritation, injection site reaction<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Drug-related nausea and/or vomiting appeared to occur more often in granulocytopenic patients than in nongranulocytopenic patients.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Nausea, vomiting, diarrhea</p>
<p><b>Rare</b> (0.01% to 0.1%): Pseudomembranous colitis</p>
<p><b>Very rare</b> (less than 0.01%): Hemorrhagic colitis, gastroenteritis, abdominal pain, glossitis, tongue papillar hypertrophy, heartburn, increased salivation</p>
<p><b>Frequency not reported</b>: Clostridium difficile-associated diarrhea, oral candidiasis, constipation</p>
<p><b>Postmarketing reports</b>: Staining of the teeth and/or tongue<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash (e.g., exanthematous)</p>
<p><b>Uncommon</b> (0.1% to 1%): Pruritus, urticaria</p>
<p><b>Rare</b> (0.01% to 0.1%): Erythema multiforme, angioedema/angioneurotic edema, exfoliative dermatitis</p>
<p><b>Very rare</b> (less than 0.01%): Hyperhidrosis, skin texture changes, candidiasis</p>
<p><b>Postmarketing reports</b>: Stevens-Johnson syndrome, toxic epidermal necrolysis</p>
<p></p>
<p>Beta-lactams:</p>
<p>-Frequency not reported: Severe cutaneous adverse reactions (including Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms [DRESS], acute generalized exanthematous pustulosis)<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Eosinophilia</p>
<p><b>Uncommon</b> (0.1% to 1%): Thrombocytosis, positive Coombs test, prolonged prothrombin time, decreased hemoglobin</p>
<p><b>Frequency not reported</b>: Increased eosinophils, increased WBC, increased platelets, decreased hemoglobin and hematocrit, increased monocytes, abnormal prothrombin time, increased lymphocytes, increased basophils, decreased neutrophils, increased/decreased platelet count, increased/decreased hematocrit, anemia</p>
<p><b>Postmarketing reports</b>: Pancytopenia, bone marrow depression, neutropenia, thrombocytopenia, leukopenia, hemolytic anemia, agranulocytosis<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Increased serum transaminases</p>
<p><b>Uncommon</b> (0.1% to 1%): Increased bilirubin</p>
<p><b>Frequency not reported</b>: Elevated ALT, elevated AST, increased/decreased bilirubin</p>
<p><b>Postmarketing reports</b>: Hepatitis (including fulminant hepatitis), jaundice, hepatic failure<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Increased alkaline phosphatase</p>
<p><b>Uncommon</b> (0.1% to 1%): Fever</p>
<p><b>Very rare</b> (less than 0.01%): Flushing, asthenia/weakness</p>
<p><b>Frequency not reported</b>: Increased LDH, decreased serum sodium, increased potassium, increased chloride, facial edema, pain, superinfection</p>
<p><b>Postmarketing reports</b>: Drug fever<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Uncommon</b> (0.1% to 1%): Seizures, myoclonic activity, dizziness, somnolence</p>
<p><b>Rare</b> (0.01% to 0.1%): Encephalopathy, paresthesia, focal tremor, hearing loss</p>
<p><b>Very rare</b> (less than 0.01%): Exacerbation of myasthenia gravis, headache, vertigo, tinnitus</p>
<p><b>Frequency not reported</b>: Myoclonus</p>
<p><b>Postmarketing reports</b>: Tremor, dyskinesia, taste perversion<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Uncommon</b> (0.1% to 1%): Hypotension</p>
<p><b>Very rare</b> (less than 0.01%): Palpitations, tachycardia, cyanosis<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Uncommon</b> (0.1% to 1%): Confusion</p>
<p><b>Postmarketing reports</b>: Psychic disturbances (including hallucinations), agitation</p><h3>Renal</h3><p><b>Uncommon</b> (0.1% to 1%): Increased BUN, increased creatinine</p>
<p><b>Rare</b> (0.01% to 0.1%): Oliguria/anuria</p>
<p><b>Postmarketing reports</b>: Acute renal failure<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Rare</b> (0.01% to 0.1%): Polyuria</p>
<p><b>Very rare</b> (less than 0.01%): Pruritus vulvae</p>
<p><b>Frequency not reported</b>: Presence of urine protein, presence of urine red blood cells, presence of urine white blood cells, presence of urine casts, presence of urine bilirubin, presence of urine urobilinogen, increased urine protein, presence of urine bacteria</p>
<p><b>Postmarketing reports</b>: Urine discoloration<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Rare</b> (0.01% to 0.1%): Anaphylactic reactions</p>
<p></p>
<p>Beta-lactams:</p>
<p>-Frequency not reported: Hypersensitivity (anaphylactic) reactions<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very rare</b> (less than 0.01%): Chest discomfort, dyspnea, hyperventilation, pharyngeal pain<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very rare</b> (less than 0.01%): Polyarthralgia, thoracic spine pain<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Zhanel GG,  Wiebe R,  Dilay L, et al. "Comparative Review of the Carbapenems." Drugs 67 (2007): 1027-1052</p><p id="ref_2">2. "Product Information. Primaxin (imipenem)." Merck &amp; Co, Inc, West Point, PA. </p><p id="ref_3">3. Embil JM,  Soto NE,  Melnick DA "A post hoc subgroup analysis of meropenem versus imipenem/cilastatin in a multicenter, double-blind, randomized study of complicated skin and skin-structure infections in patients with diabetes mellitus." Clin Ther 28 (2006): 1164-74</p><p id="ref_4">4. Calandra GB, Brown KR, Grad LC, et al "Review of adverse experiences and tolerability in the first 2,516 patients treated with imipenem/cilastatin." Am J Med 78 (1985): 73-8</p><p id="ref_5">5. Chastre J,  Wunderink R,  Prokocimer P,  Lee M,  Kaniga K,  Friedland I "Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study." Crit Care Med 36 (2008): 1089-96</p><p id="ref_6">6. Wang C, Calandra GB, Aziz MA, Brown KR "Efficacy and safety of imipenem/cilastatin: a review of worldwide clinical experience." Rev Infect Dis 7 (1985): s528-36</p><p id="ref_7">7. Calandra GB, Hesney M, Grad C "A multiclinic randomized study of the comparative efficacy, safety and tolerance of imipenem/cilastatin and moxalactam." Eur J Clin Microbiol 3 (1984): 478-87</p><p id="ref_8">8. Clissold SP, Todd PA, Campoli-Richards DM "Imipenem/cilastatin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy." Drugs 33 (1987): 185-241</p><p id="ref_9">9. Young K "Imipenem/cilastatin." Pharm Ther Forum 34 (1986): 1-3</p><p id="ref_10">10. Schmitt DV,  Leitner E,  Welte T,  Lode H "Piperacillin/Tazobactam vs Imipenem/Cilastatin in the Treatment of Nosocomial Pneumonia-a Double Blind Prospective Multicentre Study." Infection 34 (2006): 127-34</p><p id="ref_11">11. Rivera M,  Crespo M,  Teruel JL,  Marcen R,  Ortuno J "Neurotoxicity due to imipenem/cilastatin in patients on continuous ambulatory peritoneal dialysis." Nephrol Dial Transplant 14 (1999): 258-9</p><p id="ref_12">12. Lyon JA "Imipenem/cilastatin: the first carbapenem antibiotic." Drug Intell Clin Pharm 19 (1985): 894-8</p><p id="ref_13">13. Patel SA, Braun HL, Fine MS, et al "Imipenem-associated elevation of amylase and lipase." Am J Gastroenterol 84 (1989): 80-1</p><p id="ref_14">14. Larsen JW, Gabel-Hughes K, Kreter B "Efficacy and tolerability of imipenem-cilastatin versus clindamycin + gentamicin for serious pelvic infections." Clin Ther 14 (1992): 90-6</p><p id="ref_15">15. Zazgornik J, Schein W, Heimberger K, et al "Potentiation of neurotoxic side effects by coadministration of imipenem to cyclosporine therapy in a kidney transplant recipient: synergism of side effects or drug." Clin Nephrol 26 (1986): 265-6</p><p id="ref_16">16. Guglielmo BJ, Jacobs RA "Impact of dosage-monitoring system on frequency of seizures associated with imipenem-cilastatin." Am J Health Syst Pharm 53 (1996): 1097-8</p><p id="ref_17">17. Eng RH, Munsif AN, Yangco BG, et al "Seizure propensity with imipenem." Arch Intern Med 149 (1989): 1881-3</p><p id="ref_18">18. Lane M, Kania D, Rapp RP "Seizures related to use of imipenem-cilastatin." Am J Health Syst Pharm 53 (1996): 1605-6</p><p id="ref_19">19. Guglielmo BJ, Jacobs RA "Impact of dosage-monitoring system on frequency of seizures associated with imipenem-cilastatin." Am J Health Syst Pharm 53 (1996): 2097-8</p><p id="ref_20">20. Frucht S, Eidelberg D "Imipenem-induced myoclonus." Mov Disord 12 (1997): 621-2</p><p id="ref_21">21. Roberts JA,  Lipman J "Antibacterial Dosing in Intensive Care : Pharmacokinetics, Degree of Disease and Pharmacodynamics of Sepsis." Clin Pharmacokinet 45 (2006): 755-773</p><p id="ref_22">22. Campise M "Neurological complication during imipenem/cilastatin therapy in uraemic patients." Nephrol Dialysis Transplant 13 (1998): 1895-6</p><p id="ref_23">23. Job ML, Dretler RH "Seizure activity with imipenem therapy: incidence and risk factors." DICP 24 (1990): 467-9</p><p id="ref_24">24. Oriordan J, Javed M, Doherty C, Hutchinson M "Worsening of myasthenia gravis on treatment with imipenem/cilastatin." J Neurol Neurosurg Psychiatry 57 (1994): 383</p><p id="ref_25">25. Duque A, Altimiras J, Garcia-Cases C, Vidal P "Vertigo caused by intravenous imipenem/cilastatin." DICP 25 (1991): 1009</p><p id="ref_26">26. Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991): 465-8</p><p id="ref_27">27. Leo RJ, Ballow CH "Seizure activity associated with imipenem use: clinical case reports and review of the literature." DICP 25 (1991): 351-4</p><p id="ref_28">28. Hantson P, de Coninck B, Horn JL, Mahieu P "Immediate hypersensitivity to aztreonam and imipenem." Br Med J 302 (1991): 294-5</p><p id="ref_29">29. Romano A,  Viola M,  Gueant-Rodriguez RM,  Gaeta F,  Pettinato R,  Gueant JL "Imipenem in patients with immediate hypersensitivity to penicillins." N Engl J Med 354 (2006): 2835-7</p><p id="ref_30">30. Pleasants RA, Walker TR, Samuelson WM "Allergic reactions to parenteral beta-lactam antibiotics in patients with cystic fibrosis." Chest 106 (1994): 1124-8</p></div>
<div class="more-resources" id="moreResources">
<h2>More about cilastatin / imipenem</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>1 Review</li>
<li>Drug class: carbapenems</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Imipenem and cilastatin Intravenous, Intramuscular &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Primaxin IV, Primaxin IM</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Bacteremia</li>
<li>Bone infection</li>
<li>Aspiration Pneumonia</li>
<li>Bacterial Infection</li>
<li data-more-config-id="list-data-resources-conditions">... +19 more</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to cilastatin / imipenem: injectable powder for injection, intramuscular powder for injection</i></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Phlebitis/thrombophlebitis at the injection site</p><p><b>Uncommon</b> (0.1% to 1%): Pain at the injection site, erythema at the injection site, vein induration, local pain and induration at the injection site</p><p><b>Frequency not reported</b>: Infused vein infection, injection site irritation, injection site reaction<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Drug-related nausea and/or vomiting appeared to occur more often in granulocytopenic patients than in nongranulocytopenic patients.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Nausea, vomiting, diarrhea</p><p><b>Rare</b> (0.01% to 0.1%): Pseudomembranous colitis</p><p><b>Very rare</b> (less than 0.01%): Hemorrhagic colitis, gastroenteritis, abdominal pain, glossitis, tongue papillar hypertrophy, heartburn, increased salivation</p><p><b>Frequency not reported</b>: Clostridium difficile-associated diarrhea, oral candidiasis, constipation</p><p><b>Postmarketing reports</b>: Staining of the teeth and/or tongue<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash (e.g., exanthematous)</p><p><b>Uncommon</b> (0.1% to 1%): Pruritus, urticaria</p><p><b>Rare</b> (0.01% to 0.1%): Erythema multiforme, angioedema/angioneurotic edema, exfoliative dermatitis</p><p><b>Very rare</b> (less than 0.01%): Hyperhidrosis, skin texture changes, candidiasis</p><p><b>Postmarketing reports</b>: Stevens-Johnson syndrome, toxic epidermal necrolysis</p><p></p><p>Beta-lactams:</p><p>-Frequency not reported: Severe cutaneous adverse reactions (including Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms [DRESS], acute generalized exanthematous pustulosis)<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Eosinophilia</p><p><b>Uncommon</b> (0.1% to 1%): Thrombocytosis, positive Coombs test, prolonged prothrombin time, decreased hemoglobin</p><p><b>Frequency not reported</b>: Increased eosinophils, increased WBC, increased platelets, decreased hemoglobin and hematocrit, increased monocytes, abnormal prothrombin time, increased lymphocytes, increased basophils, decreased neutrophils, increased/decreased platelet count, increased/decreased hematocrit, anemia</p><p><b>Postmarketing reports</b>: Pancytopenia, bone marrow depression, neutropenia, thrombocytopenia, leukopenia, hemolytic anemia, agranulocytosis<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Increased serum transaminases</p><p><b>Uncommon</b> (0.1% to 1%): Increased bilirubin</p><p><b>Frequency not reported</b>: Elevated ALT, elevated AST, increased/decreased bilirubin</p><p><b>Postmarketing reports</b>: Hepatitis (including fulminant hepatitis), jaundice, hepatic failure<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Increased alkaline phosphatase</p><p><b>Uncommon</b> (0.1% to 1%): Fever</p><p><b>Very rare</b> (less than 0.01%): Flushing, asthenia/weakness</p><p><b>Frequency not reported</b>: Increased LDH, decreased serum sodium, increased potassium, increased chloride, facial edema, pain, superinfection</p><p><b>Postmarketing reports</b>: Drug fever<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Uncommon</b> (0.1% to 1%): Seizures, myoclonic activity, dizziness, somnolence</p><p><b>Rare</b> (0.01% to 0.1%): Encephalopathy, paresthesia, focal tremor, hearing loss</p><p><b>Very rare</b> (less than 0.01%): Exacerbation of myasthenia gravis, headache, vertigo, tinnitus</p><p><b>Frequency not reported</b>: Myoclonus</p><p><b>Postmarketing reports</b>: Tremor, dyskinesia, taste perversion<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Uncommon</b> (0.1% to 1%): Hypotension</p><p><b>Very rare</b> (less than 0.01%): Palpitations, tachycardia, cyanosis<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Uncommon</b> (0.1% to 1%): Confusion</p><p><b>Postmarketing reports</b>: Psychic disturbances (including hallucinations), agitation</p><h3>Renal</h3><p><b>Uncommon</b> (0.1% to 1%): Increased BUN, increased creatinine</p><p><b>Rare</b> (0.01% to 0.1%): Oliguria/anuria</p><p><b>Postmarketing reports</b>: Acute renal failure<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Rare</b> (0.01% to 0.1%): Polyuria</p><p><b>Very rare</b> (less than 0.01%): Pruritus vulvae</p><p><b>Frequency not reported</b>: Presence of urine protein, presence of urine red blood cells, presence of urine white blood cells, presence of urine casts, presence of urine bilirubin, presence of urine urobilinogen, increased urine protein, presence of urine bacteria</p><p><b>Postmarketing reports</b>: Urine discoloration<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Rare</b> (0.01% to 0.1%): Anaphylactic reactions</p><p></p><p>Beta-lactams:</p><p>-Frequency not reported: Hypersensitivity (anaphylactic) reactions<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very rare</b> (less than 0.01%): Chest discomfort, dyspnea, hyperventilation, pharyngeal pain<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very rare</b> (less than 0.01%): Polyarthralgia, thoracic spine pain<sup>[Ref]</sup></p><p id="ref_1">1. Zhanel GG,  Wiebe R,  Dilay L, et al. "Comparative Review of the Carbapenems." Drugs 67 (2007): 1027-1052</p><p id="ref_2">2. "Product Information. Primaxin (imipenem)." Merck &amp; Co, Inc, West Point, PA. </p><p id="ref_3">3. Embil JM,  Soto NE,  Melnick DA "A post hoc subgroup analysis of meropenem versus imipenem/cilastatin in a multicenter, double-blind, randomized study of complicated skin and skin-structure infections in patients with diabetes mellitus." Clin Ther 28 (2006): 1164-74</p><p id="ref_4">4. Calandra GB, Brown KR, Grad LC, et al "Review of adverse experiences and tolerability in the first 2,516 patients treated with imipenem/cilastatin." Am J Med 78 (1985): 73-8</p><p id="ref_5">5. Chastre J,  Wunderink R,  Prokocimer P,  Lee M,  Kaniga K,  Friedland I "Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study." Crit Care Med 36 (2008): 1089-96</p><p id="ref_6">6. Wang C, Calandra GB, Aziz MA, Brown KR "Efficacy and safety of imipenem/cilastatin: a review of worldwide clinical experience." Rev Infect Dis 7 (1985): s528-36</p><p id="ref_7">7. Calandra GB, Hesney M, Grad C "A multiclinic randomized study of the comparative efficacy, safety and tolerance of imipenem/cilastatin and moxalactam." Eur J Clin Microbiol 3 (1984): 478-87</p><p id="ref_8">8. Clissold SP, Todd PA, Campoli-Richards DM "Imipenem/cilastatin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy." Drugs 33 (1987): 185-241</p><p id="ref_9">9. Young K "Imipenem/cilastatin." Pharm Ther Forum 34 (1986): 1-3</p><p id="ref_10">10. Schmitt DV,  Leitner E,  Welte T,  Lode H "Piperacillin/Tazobactam vs Imipenem/Cilastatin in the Treatment of Nosocomial Pneumonia-a Double Blind Prospective Multicentre Study." Infection 34 (2006): 127-34</p><p id="ref_11">11. Rivera M,  Crespo M,  Teruel JL,  Marcen R,  Ortuno J "Neurotoxicity due to imipenem/cilastatin in patients on continuous ambulatory peritoneal dialysis." Nephrol Dial Transplant 14 (1999): 258-9</p><p id="ref_12">12. Lyon JA "Imipenem/cilastatin: the first carbapenem antibiotic." Drug Intell Clin Pharm 19 (1985): 894-8</p><p id="ref_13">13. Patel SA, Braun HL, Fine MS, et al "Imipenem-associated elevation of amylase and lipase." Am J Gastroenterol 84 (1989): 80-1</p><p id="ref_14">14. Larsen JW, Gabel-Hughes K, Kreter B "Efficacy and tolerability of imipenem-cilastatin versus clindamycin + gentamicin for serious pelvic infections." Clin Ther 14 (1992): 90-6</p><p id="ref_15">15. Zazgornik J, Schein W, Heimberger K, et al "Potentiation of neurotoxic side effects by coadministration of imipenem to cyclosporine therapy in a kidney transplant recipient: synergism of side effects or drug." Clin Nephrol 26 (1986): 265-6</p><p id="ref_16">16. Guglielmo BJ, Jacobs RA "Impact of dosage-monitoring system on frequency of seizures associated with imipenem-cilastatin." Am J Health Syst Pharm 53 (1996): 1097-8</p><p id="ref_17">17. Eng RH, Munsif AN, Yangco BG, et al "Seizure propensity with imipenem." Arch Intern Med 149 (1989): 1881-3</p><p id="ref_18">18. Lane M, Kania D, Rapp RP "Seizures related to use of imipenem-cilastatin." Am J Health Syst Pharm 53 (1996): 1605-6</p><p id="ref_19">19. Guglielmo BJ, Jacobs RA "Impact of dosage-monitoring system on frequency of seizures associated with imipenem-cilastatin." Am J Health Syst Pharm 53 (1996): 2097-8</p><p id="ref_20">20. Frucht S, Eidelberg D "Imipenem-induced myoclonus." Mov Disord 12 (1997): 621-2</p><p id="ref_21">21. Roberts JA,  Lipman J "Antibacterial Dosing in Intensive Care : Pharmacokinetics, Degree of Disease and Pharmacodynamics of Sepsis." Clin Pharmacokinet 45 (2006): 755-773</p><p id="ref_22">22. Campise M "Neurological complication during imipenem/cilastatin therapy in uraemic patients." Nephrol Dialysis Transplant 13 (1998): 1895-6</p><p id="ref_23">23. Job ML, Dretler RH "Seizure activity with imipenem therapy: incidence and risk factors." DICP 24 (1990): 467-9</p><p id="ref_24">24. Oriordan J, Javed M, Doherty C, Hutchinson M "Worsening of myasthenia gravis on treatment with imipenem/cilastatin." J Neurol Neurosurg Psychiatry 57 (1994): 383</p><p id="ref_25">25. Duque A, Altimiras J, Garcia-Cases C, Vidal P "Vertigo caused by intravenous imipenem/cilastatin." DICP 25 (1991): 1009</p><p id="ref_26">26. Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991): 465-8</p><p id="ref_27">27. Leo RJ, Ballow CH "Seizure activity associated with imipenem use: clinical case reports and review of the literature." DICP 25 (1991): 351-4</p><p id="ref_28">28. Hantson P, de Coninck B, Horn JL, Mahieu P "Immediate hypersensitivity to aztreonam and imipenem." Br Med J 302 (1991): 294-5</p><p id="ref_29">29. Romano A,  Viola M,  Gueant-Rodriguez RM,  Gaeta F,  Pettinato R,  Gueant JL "Imipenem in patients with immediate hypersensitivity to penicillins." N Engl J Med 354 (2006): 2835-7</p><p id="ref_30">30. Pleasants RA, Walker TR, Samuelson WM "Allergic reactions to parenteral beta-lactam antibiotics in patients with cystic fibrosis." Chest 106 (1994): 1124-8</p><h2>More about cilastatin / imipenem</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>1 Review</li>
<li>Drug class: carbapenems</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Imipenem and cilastatin Intravenous, Intramuscular &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Bacteremia</li>
<li>Bone infection</li>
<li>Aspiration Pneumonia</li>
<li>Bacterial Infection</li>
<li data-more-config-id="list-data-resources-conditions">... +19 more</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>